NEW YORK (GenomeWeb News) — Translational genomics company Horizon Discovery will use its X-MAN technology to screen a number of drug compounds and potential patient groups for Actelion Pharmaceuticals.
The agreement covers screening of “a number of Actelion’s lead compounds on a wide panel of genotypes,” Horizon said. The aim is to enable the drug company to predict the selectivity of their compounds against patient genotypes, the drug mechanisms conferred by secondary mutations, and the patient groups that are most likely to respond in clinical trials.
Actelion will pay Horizon an undisclosed sum. The companies will begin work on the project in January 2009, said Horizon.
Horizon Discovery hopes that the project will help it “further prove the potential of our human X-Man models in a screening environment,” Horizon’s Commercial Director, Darrin Disley, said in a statement.
Financial terms of the agreement were not released.